Designing and enabling pragmatic clinical trials in cystic fibrosis to simplify the burden of treatment

点击翻译按钮获取中文摘要

Cystic fibrosis (CF) is an inherited, life-shortening disease affecting around 10,000 people in the UK (1). In the lungs, thick sticky secretions and chronic infection lead to a progressive deterioration in health. People with CF take multiple treatments on a daily basis (taking a total of 1-2 hours per day even when 'well') and simplifying the treatment burden was voted the highest research priority by the CF community (2). New treatments for CF which target the underlying cause of the disease can now significantly change the health profile and outlook for people with CF, but clinical trials to date have evaluated these new drugs by adding them to existing treatments. This may mean that some existing burdensome treatments (such as nebulised therapies) are no longer necessary. Efficient non-burdensome clinical trials are needed to provide evidence to reduce treatment burden. A potential 'pragmatic' platform to evaluate this involves the UK CF Registry, which includes routinely collected data from over 99% of the UK CF population (1). In 2016 it embarked on the first randomised Registry clinical trial in infants with CF, demonstrating that a CF Registry trial is feasible but opportunities in older children and adults with established disease have not been evaluated.In this Fellowship I will develop a Registry platform for clinical trials that can address questions relating to simplifying treatment burden in CF, as an exemplar for other chronic diseases. New clinical trial designs will be explored that may be more appropriate than traditional approaches, with an emphasis on trials that use routinely collected data and outcomes relevant to patients, and lay and professional perspectives on these approaches will be sought. This will include considerations relating to informed consent and identification of eligible trial participants, as well as outcomes captured during routine care or requiring additional data capture (e.g. patient reported measures of treatment burden). Results will inform Registry development work to create modules that will 'bolt on' to the existing web-based infrastructure of the UK CF Registry, to create a platform capable of hosting multiple randomised clinical trials. During my Fellowship I will investigate the interfaces between Registries and electronic patient records in relation to trial databases and regulatory requirements for these types of clinical trials. At a local level, there has been a significant investment in the informatics infrastructure at Great Ormond Street Hospital (GOSH) and its Digital Research Environment, which allow sophisticated data research. A GOSH CF clinic population of around 200 children and young people will allow further investigation of how Registry trials may interact with electronic health records and data integration from multiple sources.At a national level, I will lead two CF Registry feasibility studies to determine whether this research would make it efficient, acceptable and less costly to run clinical trials to simplify treatment burden, designed according to outputs from the above. These studies will assess the feasibility of running the trials within NHS CF centres of care, consent processes, and Registry capability for identifying patient eligibility, patient recruitment, and outcome data collection (patient reported and safety). These results will help plan large randomised controlled trials, for the UK CF community. I look forward to working with existing national and international collaborators, and to developing new links as I work towards transforming the investigator-led CF clinical trials landscape as a UK Research and Innovation Future Leaders Fellow. The research excellence environment within the Great Ormond Street Institute of Child Health will be an excellent host for this Fellowship.References:(1) UK CF Registry Annual Data Report 2018, Cystic Fibrosis Trust (published Aug 2019)(2) Rowbotham N et al. Thorax 2018;73:388-9